EuroBiotech Report—AZ-Transgene, Bicycle IPO, Alentis round, ReNeuron and trial transparency

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with AstraZeneca, which teamed up with Transgene to add five oncolytic viruses to its pipeline. AstraZeneca plans to combine the drugs with its cancer assets. Elsewhere, one of AstraZeneca's partners, Bicycle Therapeutics, filed to raise $86 million (€77 million) in a Nasdaq IPO. Alentis Therapeutics raised a CHF 12.5 million series A round and named an ex-Ablynx executive as CEO. ReNeuron posted updated data on its vision loss cell therapy. Campaigners found top European universities are failing to comply with trial data reporting requirements. And more. — Nick Taylor
 
1. AstraZeneca ups oncolytic virus activity with Transgene deal

AstraZeneca has teamed up with Transgene to develop oncolytic virus candidates. The Big Pharma is paying $10 million (€9 million) upfront to get Transgene to apply its oncolytic virus expertise and technologies to the development of five assets. 
 
2. Bicycle files for $86M IPO to fund trials of novel drug conjugates

Bicycle Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The British biotech wants the money to prepare for phase 2 and 3 clinical trials of its lead anticancer candidate, BT1718.
 
3. Alentis raises series A round to advance drug against novel liver disease target

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

Alentis Therapeutics has raised CHF 12.5 million ($12.2 million) to take an advanced liver disease drug toward clinical development. The series A tees a team led by ex-Ablynx CBO Markus Ewert up to advance a lead antibody against a previously undiscovered liver target. 
 
4. ReNeuron climbs on updated vision loss cell therapy data
 
ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.

5. European universities fail to report results for 83% of trials

The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results, according to a registry analysis.
 
And more articles of note>>    

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.